Previous Close | 5.29 |
Open | 5.20 |
Bid | 5.12 x 1400 |
Ask | 5.29 x 1100 |
Day's Range | 5.19 - 5.39 |
52 Week Range | 0.97 - 5.39 |
Volume | |
Avg. Volume | 106,853 |
Market Cap | 138.797M |
Beta (5Y Monthly) | 1.08 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.34 |
Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 1.40 |
Subscribe to Yahoo Finance Plus to view Fair Value for IMRA
Imara Inc., the blood disorder-focused company that earlier this year cut its staff to just six people, will be no more following a reverse merger with a Colorado biotech.
Enliven Therapeutics Inc and Imara Inc (NASDAQ: IMRA) agreed to merge in an all-stock transaction. The combined company will focus on advancing Enliven's pipeline of precision oncology product candidates. Enliven is advancing two parallel lead product candidates: ELVN-001 for chronic myeloid leukemia. ELVN-002 for HER2 mutant lung cancer and other HER2-driven tumor types. In September, Imara divested tovinontrine (IMR-687) and all other assets related to its PDE9 program to Cardurion Pharmaceuti
Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing Enliven’s portfolio of precision oncology programsCombined company is expected to have a cash balance of approximately $300 million at close, which is expected to provide cash runway through multiple clinical milestones and into early 2026Planned concurrent financing of approximately $165 million co-led by new investors Fairmount and Venrock Healthcare Capital Partners, with participation from additiona